Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trans-Mitral Valve Repair Gains Medicare Coverage-With-Evidence Proposal

This article was originally published in The Gray Sheet

Executive Summary

A new draft national Medicare coverage policy offers to pay for transcatheter mitral valve repair procedures with devices like Abbott’s MitraClip only if they are conducted by a qualified heart team and are part of a national registry.

You may also be interested in...



MitraClip Medicare Gains: National Coverage Follows Bonus Payment Decision

CMS finalized a national coverage determination for transcatheter mitral valve repair, conditioned on a registry and on minimum facility and experience requirements for hospitals. The policy follows close behind a new-technology add-on payment granted to Abbott’s MitraClip device.

TAVR Gets Love, MitraClip Gets None In Medicare Inpatient Proposal

CMS proposes to grant new hospital inpatient payment categories for transcatheter valve replacements, a potential boon to Edwards’ and Medtronic’s devices. But the Medicare agency continues to stand firm against upgrading payment levels for Abbott’s MitraClip percutaneous mitral valve repair procedure.

News Briefs: Approvals For Abbott’s MitraClip, Allergan’s Juvéderm; Diagnostics News

FDA approved Abbott’s MitraClip to treat mitral regurgitation and Allergan’s Juvéderm Voluma XC facial filler to temporary correct volume-loss. Hepatitis C testing will be mandatory in New York. More news.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT033011

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel